52°09′56″N 4°28′02″E / 52.1655°N 4.4673°E / 52.1655; 4.4673
| [REDACTED] | |
 | |
| Formerly | Crucell |
|---|---|
| Company type | Subsidiary |
| Industry | Biotechnology |
| Founded | 2000; 25 years ago (2000) |
| Headquarters | Archimedesweg 4, Leiden, Netherlands |
| Key people |
|
| Products | Vaccines and antibodies |
| Parent | Johnson & Johnson |
| Website | www |
![[REDACTED]](https://u3vuiephb.global.ssl.fastly.net/File:Janssen_Pharmaceuticals_logo.svg){kind=link}
Janssen Vaccines, formerly Crucell, is a biotechnology company specializing in vaccines and biopharmaceutical technologies. It was formed when Johnson & Johnson acquired the Dutch biotech company Crucell. Janssen Vaccines is part of Johnson & Johnson Innovative Medicine business segment.
History
In 1993 Introgene, Crucell's predecessor, was established as a spin-off of Leiden University. The company formed a partnership with Genzyme to collaborate on its vector technology and viral-based products. In 1999 the company founded Galapagos Genomics as a joint venture together with Tibotec. In 2000 IntroGene acquired U-Bisys to form Crucell.
In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.
On 7 January 2009 Crucell released a press release saying Crucell and Wyeth were in discussion on a merger of the two companies. On 26 January 2009 Crucell released another press release saying the discussions on a combination of Crucell and Wyeth was discontinued due to Pfizer's acquisition of Wyeth.
In September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 million in order to collaborate on the development of a flu vaccine. This followed Crucell's discovery of CR6261, a potent human antibody that neutralizes a broad range of influenza A viruses. J&J acquired the rest of the company in October 2010, taking its stake to over 95% by February 2011 and delisting the company from stock exchanges two months later.
After the takeover by Johnson & Johnson in 2011, Crucell was assigned to Janssen Pharmaceuticals division. In 2014, the subsidiary was renamed from Crucell to Janssen Vaccines.
COVID-19 vaccine development
Main article: Janssen COVID-19 vaccineJanssen Vaccines in Leiden developed the COVID-19 vaccines for Johnson & Johnson. Initial production of the vaccine is happening at Janssen Biotech in Leiden, Netherlands. The vaccine stands out because it is the first single-shot vaccine against COVID-19 that was developed during the COVID-19 pandemic.
References
- Gray-Block, Aaron (28 September 2009). "Johnson & Johnson buys 18 pct stake in Crucell". Reuters. Retrieved 28 September 2009.
- Solsman, Joan E. (17 February 2011). "J&J: Sufficient Number Of Crucell Holders Tender Shares". The Wall Street Journal. Dow Jones Newswires. Retrieved 27 February 2011.
- "J&J aiming to buy vaccine maker Crucell for $2.3 billion". Reuters. 17 September 2010.
- Gray-Block, Aaron (11 April 2011). "Crucell to be delisted after J&J buyout". Reuters. Retrieved 16 April 2011.
- "Crucell". DevEx. 2015.
- "Janssen Vaccines AG". Company Profiles. Bloomberg. 2020.